Integer vs LivaNova
ITGR and LIVN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ITGR and LIVN compare
LivaNova is the larger company, worth 1.2 times as much as Integer ($5.0B against $4.3B).
On earnings, LivaNova is cheaper: it trades at 30.0× trailing earnings, against 42.4× for Integer.
LivaNova grew revenue faster over the last twelve months (11.7% versus −0.31% for Integer).
LivaNova keeps more of each dollar of sales as profit, with a net margin of 13.0% compared with 5.7% at Integer.
LivaNova scores higher on the StockData Score (13 against 8 for Integer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ITGR | LIVN |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $5.0B |
| Share price | $126.42 | $90.20 |
| Change, 1 year | 81.1% | 71.2% |
| Change, 5 years | 40.9% | 4.8% |
| Beta (5Y) | 0.78 | 1.07 |
| Employees | 11K | 3,300 |
| StockData Score | ||
| Total score | 8 | 13 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 42.4× | 30.0× (better) |
| P/S | 2.4× (better) | 3.3× |
| P/B | 2.5× (better) | 3.6× |
| EV/EBITDA | 19.0× (better) | 29.1× |
| P/FCF | 52.5× | 38.5× (better) |
| PEG | 3.20 | – |
| FCF yield | 1.9% | 2.6% (better) |
| Fair value | $102.93 | $70.48 |
| Margin of safety | −22.8% (better) | −28.0% |
| Growth | ||
| Revenue growth (TTM) | −0.31% | 11.7% (better) |
| Revenue growth, 5Y average | 11.5% (better) | 8.2% |
| Net income growth (TTM) | 19.3% | – |
| EPS growth (TTM) | 24.7% | – |
| EPS growth, 5Y average | 4.4% | – |
| Profitability | ||
| Gross margin | 24.6% | 67.8% (better) |
| Operating margin | 8.2% | 10.7% (better) |
| Net margin | 5.7% | 13.0% (better) |
| FCF margin | 4.5% | 8.6% (better) |
| Return on equity | 6.0% | 15.5% (better) |
| Return on invested capital | 5.0% | 15.8% (better) |
| Financial health | ||
| Debt / equity | 0.71 | 0.22 (better) |
| Net debt / EBITDA | 4.16 (better) | −1.63 |
| Interest coverage | 3.9× | 5.1× (better) |
| Current ratio | 3.98 (better) | 1.46 |
| Altman Z-score | 2.88 (better) | 2.62 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 2.3% | – |
| Shareholder yield | 2.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 120% | 108% |
| Held by insiders | 15.1% | 0.48% |
| Insider net buying, 12 months | −$5.2M | −$1.0M (better) |
| Short interest, % of float | 11.9% | 11.6% |
Go deeper
- ITGR stock overview
- ITGR income statement
- ITGR valuation and score
- LIVN stock overview
- LIVN income statement
- LIVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.